


## Indian Pharmaceutical Market Quarterly Insights – Q4 2023<sub>(Oct-Dec)</sub>

Report Release Date: Feb 2024 Dataset: TSA December 2023

© 2024. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.

# IPM's 10% growth has come largely on the back of price (4%), followed by NI (3%)



Highlights of the year 2023



Acute therapies like AI & VMN have shown improved volumes in 2023 (-1%- $\rightarrow$ 4%) while chronic therapies are driven by strong volumes( Cardiac, Urology, Respi & Antineoplast )



Seasonal peak seen in Q3(Jul-Sep) across all years majorly due to Anti-infective & Cough & Cold segments. Q1 has shown the maximum incremental growth in 2023



Indian companies dominate with 83% share growing at 10% PPG with Aristo moving up 2 ranks, Intas, Glenmark & Ipca have gained 1 rank each amongst the top companies while MNC have grown at 7% PPG due to Novartis, MSD, BI & Abbvie showing a degrowth



(0)

**Top 10 companies & > 500 Cr brands** are growing well at 10% & 11% esp acute brands **like Augmentin, Monocef, Pan & Chronic brand like Foracort** 

West zone has gained back after a **degrowth in 2022** due to strong growth in **Mumbai, Maharashtra & MP** 



MAT Dec 2023 vs. MAT Dec 2022 as well as Qtr. Oct- Dec 2023 vs. Qtr. Oct- Dec 2022 growth Source: IQVIA TSA Dec 2023

### Market reflected growth of 8% in Q4 2023



- Overall IPM market size: ₹213K Cr. (MAT Dec); ₹ 55K Cr (Q4 Dec 2023)
- Growth in Sales Value Previous Period Growth ('PPG'): 10% (MAT); 8% (Q4 2023)
- Chronic TAs growth (9% Q4) outperformed Acute TAs growth (8% Q4) in 2023



#### **Chronic Therapies**

- Amongst Chronic TAs, Cardiac registered growth of 9% (PPG) followed by Neuro / CNS 9% (PPG) and Chronic Respiratory 11% (PPG).
- Antineoplast, Urology & Pain also registered double digit growth



#### Acute Therapies

- Anti-infectives led the growth for Acute TAs with a growth of 9% (PPG) followed by Gastro which also grew at 9% (PPG)
- Derma, Acute Pain, Acute Respiratory & Gynae grew in single digits




- Relative performance: Indian Pharma Cos grew at 9% (PPG) compared to MNCs which grew at 7% (PPG) for Q4 2023
- Intas, Macleods & Aristo reflected good growth among Top Indian Pharma Co's while Abbott, Sanofi, Janssen & AstraZeneca reflected good growths among Top MNC Pharma Co's



Number of new launches have increased by 17% in 2023 as compared to 2022


#### MAT Progress, Val ₹ '000 Cr.






10%





8%

## Acute market growth of 8% majorly due to growth from AI, Gastro and VMN therapies






3

Acute


### Chronic therapies also displayed growth of 9% (PPG)






## **North and South zones continue to be highest contributing zones.**

## Extra Urban market, Metro & Class 1 grew at 8% each.



- North & South are leading zones by contribution; North & South growing at 8% PPG each with most incremental coming from Uttar Pradesh, Delhi, Tamil Nadu, Telangana, and Karnataka.
- East zone's growth of 8% was driven by West Bengal, Orissa and Chattisgarh whereas Bihar grew at 6% & Kolkata & Assam grew at 7% (PPG)
- West zone showed growth of 9% due to Maharashtra growing at 11%. However, Gujarat & Mumbai grew at 8%
- Amongst the top 15 regions, Uttar Pradesh (8% PPG), Maharashtra (11% PPG), West Bengal (10% PPG), Karnataka (8% PPG), Delhi (12% PPG), Tamil Nadu ( 13% PPG) Telangana (11% PPG), Delhi (12% PPG)Madhya Pradesh (9% PPG), Gujarat (8% PPG) were the top growing regions.



- Extra Urban reflected growth of 8% PPG
- Metros and Class 1 both grew at 8% PPG each
- Metros indicated higher growths primarily led by Delhi (12% PPG),Hyderabad (9% PPG), Bangalore (10% PPG), Pune (12% PPG), Ahmedabad (15% PPG) ,Agra (16% PPG) & Ludhiana (16% PPG)



### Thank You

To learn more about Market drivers, current and emerging trends, current growth patterns, and market challenges contact us via https://bit.ly/3aEILzC

